and Inflammatory Neuropathies
Chronic Inflammatory Demyelinating Polyneuropathy
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is the most common treatable chronic neuropathy worldwide, with a prevalence ranging from about 1 to 9 cases per 100 000. CIDP typically presents a relapsing or progressive neuropathy with proximal and distal weakness which develops over at least an 8-week period. CIDP is classed as an autoimmune disorder in which a dysimmune response is directed towards components of the peripheral nerve causing demyelination, Node of Ranvier and/or axonal damages. The exact mechanisms underlying the
development of immunopathology remain to be defined. And because of the multiple phenotypic variation and clinical presentation, the identification of the pathogenic mechanisms remains complicated.
While many patients can be successfully treated (plasma derivatives, corticosteroids, plasma exchange, immunosuppressives treatment) with current therapies, some do not respond or have lasting disability.
In Europe, there are centers of expertise for this type of pathology. EPODIN is mobilized to promote access to the best diagnostic and therapeutic standards throughout Europe.